Bot Chart, page-10726

I think you're confusing my $30 co-pay comment with the total cost of Ecclock, Kaken are estimating 215,000 prescriptions.
My point is the 287,000 number from EH is straight up fiction. You just can't annualise quarters in Hyperhidrosis, theres significant seasonality which is why Kaken don't.

Absoluetly SB will outsell Ecclock this year, I suspect 215 vs 150, we will never know the data is private as of the end of last quarter. But I'm not concerned with any of that in my previous post, I'm talking about comparing Rapifort and Qbrexza, forget SB all together. When you do that the data shows that its not a matter of multiplying for population but dividing for affordability.

48,000 units in Japan

25,000 units in the US

And Japan is well and truely still in the ramp up phase.

So for a product which i conced is inferior but still a very good proxy for SB in both price and efficacy we see that US sales are half of Japan, yet for some reason were to beleive that SB will be totally different and infact you'll multiply by 3!

I think thats an incredible claim to make and is infact the one lacking in evidence.

I will concede I shouldn't have had a go at you the other day, I thought for some reason what you quoted was your own not from a report, so I apologise.